Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT01221935
First received: October 13, 2010
Last updated: January 25, 2011
Last verified: January 2011

October 13, 2010
January 25, 2011
September 2009
January 2010   (final data collection date for primary outcome measure)
  • 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01221935 on ClinicalTrials.gov Archive Site
  • Incidence of adverse events and Incidence of discontinuation due to adverse events [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Percent of patients experiencing relapse [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Length of time to relapse [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Percent of discontinuation / medication switches due to lack of efficacy [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Subjective physician assessment of symptom control [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
A Retrospective Study To Evaluate The Current Utilization Of Desvenlafaxine Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

The goal of this observational study is to learn about how Pristiq is currently being used in general practice and how psychiatrists and primary care physicians currently perceive Pristiq in terms of efficacy, tolerability, and adherence compared to other treatments for major depressive disorder (MDD).

It is retrospective patient chart study among psychiatrists and primary care physicians (PCPs) treating patients suffering from major depressive disorder (MDD). Physicians will be asked general medical questions in order to quantify their prescribing behavior and their perception of treatment performance. A retrospective patient chart review will then be performed and patient data will be collected to document patient characteristics and actual treatment outcomes. Upon qualification, specific instructions for chart review will be provided. Once the identified charts are pulled, the physicians are instructed to continue with the on-line survey. In total, there will be approximately 450 psychiatrists and 450 primary care physicians participating in this trial.

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

patient charts from psychiatrists and primary care physicians (PCPs) treating patients suffering from major depressive disorder (MDD).

Major Depressive Disorder
  • Other: Pristiq first-line treatment charts
    300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
  • Other: Pristiq second-line treatment charts
    800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
  • Other: SNRI or SSRI first-line treatment charts
    800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
  • Other: SNRI or SSRI second-line treatment charts
    800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
  • Patients initiated on Pristiq as a first line treatment
    Intervention: Other: Pristiq first-line treatment charts
  • Patients initiated on Pristiq as a 2nd-line treatment
    Intervention: Other: Pristiq second-line treatment charts
  • Patients initiated on a SNRI or SSRI as a first-line treatment
    Intervention: Other: SNRI or SSRI first-line treatment charts
  • Patients initiated on a SNRI or SSRI as a 2nd-line treatment
    Intervention: Other: SNRI or SSRI second-line treatment charts
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2701
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be adult, diagnosed with major depressive disorder and treated with pharmacotherapy.
  • Physicians must be either a psychiatrist or a primary care physician, a prescriber of Pristiq, have at least 3 charts representing the 4 identified patient types, have been in clinical practice between 4 and 35 years, primarily office based (50%+), not participated in a research study relating to antidepressants or antidepressant therapy within the past month, not a consultant or have a professional relationship with a pharmaceutical company other than for clinical trials or speaking engagements, and not be employed by of affiliated with an advertising agency, market research company, or pharmaceutical company.

Exclusion Criteria:

  • Patients who have not been treated for depression.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01221935
3151A1-4431, B2061039
No
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP